CEO SUMMARY: Two fascinating aspects about the AmeriPath story are: 1) the strategy to boost share values; and 2) the strategy to develop profitable pathology revenues. With managed healthcare transforming pathology at an astounding rate, will AmeriPath succeed in both strategies?
DURING THE LAST YEAR, intense curiosity swirled about AmeriPath, Inc. Pathologists heard plenty of rumors
Subscriber-Only Content. Please Log In.
You are trying to access subscribers-only content. If you are a subscriber, please log in.
If you are not a subscriber, click here to see subscription offers.
Subscribers will have instant access to the Dark Report library, 1997-the present, giving you the most convenient, accessible archive available in laboratory business intelligence today!
To read our FREE article previews, go to The Dark Report Insider.